ClinicalTrials.gg
CompletedNCT01209286Updated Mar 6, 2017Results posted

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

A Phase 2 interventional study of Blinatumomab in B-ALL, sponsored by Amgen Research (Munich) GmbH. Completed at 9 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
43rd of 61
36 · median 67
Started
2010
with 1 other
Phase 2
30 of 61
10 open now
Registered
3rd of 61
by date
Lead sponsor
5 of 61
Amgen Research (Munich) GmbH

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 43rd largest by enrollment, is one of 2 that started in 2010, is one of 30 in phase 2, and was the 3rd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the bispecific T-cell engager blinatumomab is effective, safe and tolerable in the treatment of patients with relapsed/refractory B-precursor ALL.

Read the detailed description

Relapsed/refractory B-precursor ALL in adult patients is an aggressive malignant disease with dismal prognosis and unmet medical need. Additional therapeutic approaches are urgently needed. Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against CD19 expressing cells. The purpose of this study is to investigate the efficacy, safety and tolerability of different doses of the bispecific T-cell engager blinatumomab in adult patients with relapsed/refractory B-precursor ALL. Patrticipants will receive up to five 4-week cycles of intravenous blinatumomab treatment.

03

Conditions studied

  • B-ALL

Keywords

  • Blinatumomab
  • B-ALL
  • adult ALL
  • relapsed ALL
  • refractory ALL
  • Leukemia
  • ALL
  • Lymphatic diseases
  • Lymphoproliferative disorders
  • bispecific antibody
  • anti-CD19
  • Immunotherapeutic treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with B-precursor ALL after at least induction and consolidation or having refractory disease
  • More than 5% blasts in bone marrow
  • (ECOG) performance status ≤ 2
  • of ≥ 12 weeks

Exclusion criteria

Exclusion Criteria:

  • History or presence of central nervous system (CNS) pathology
  • Infiltration of cerebrospinal fluid (CSF) by ALL
  • /allogeneic hematopoietic stem cell transplantation (HSCT) within six weeks/three months prior to start of blinatumomab treatment
  • Active (GvHD)
  • Patients with Philadelphia chromosome (Ph)+ ALL eligible for treatment with dasatinib or imatinib
  • Cancer chemotherapy within two weeks prior to start of blinatumomab treatment
  • Immunotherapy (e.g. rituximab) within four weeks prior to start of blinatumomab treatment
  • Infection with (HIV) or (HBsAg positive) or virus (anti-HCV positive)
  • Pregnant or nursing women
  • Previous treatment with blinatumomab
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Blinatumomab 15 μg

    Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.

    Biological: Blinatumomab

  • Experimental
    Blinatumomab 5/15 μg

    Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.

    Biological: Blinatumomab

  • Experimental
    Blinatumomab 5/15/30 μg

    Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.

    Biological: Blinatumomab

Interventions

  • BiologicalBlinatumomab

    Continuous intravenous infusion over four weeks per treatment cycle

    Also known as: AMG103, MT103, BLINCYTO™

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

    At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: Complete Response/Remission (CR): * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Full recovery of peripheral blood counts: * Platelets \> 100,000/μL * Hemoglobin ≥ 11 g/dL * Absolute neutrophil count (ANC) \> 1,500/μL Complete Remission with only Partial Hematological Recovery (CRh\*): * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Partial recovery of peripheral blood counts: * Platelets \> 50,000/μL * Hemoglobin ≥ 7 g/dL * ANC \> 500/μL.

    Time frame: Within the first 2 cycles of treatment, 12 weeks

Secondary outcomes

  1. Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment

    At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete Response/Remission (CR) was defined by the following criteria: * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Full recovery of peripheral blood counts: * Platelets \> 100,000/μL * Hemoglobin ≥ 11 g/dL * Absolute neutrophil count (ANC) \> 1,500/μL

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  2. Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

    At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete remission with only partial hematological recovery (CRh\*) was defined by the following criteria: * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Partial recovery of peripheral blood counts: * Platelets \> 50,000/μL * Hemoglobin ≥ 7 g/dL * ANC \> 500/μL.

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  3. Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment

    At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Partial remission was defined by the following criteria: • Bone marrow blasts ≤ 25%

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  4. Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study

    A minimal residual disease (MRD) response is defined as MRD \< 10\^-4 blasts/nucleated cells based on polymerase chain reaction (PCR) evaluation of individual rearrangements of immunoglobulin or T cell receptor genes.

    Time frame: During the core study treatment period (up to 30 weeks).

  5. Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab

    The percentage of participants who underwent immediate allogeneic HSCT (defined as those in remission who undergo HSCT without receiving any other treatments) after having discontinued or completed the core study.

    Time frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days

  6. Time to Hematological Relapse

    Time to hematological relapse was measured for participants who achieved a CR or CRh\* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their day of death. Hematological Relapse was defined as: * Proportion of blasts in bone marrow \> 5% * Extramedullary relapse. Time to hematological relapse was analyzed by Kaplan-Meier methods.

    Time frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.

  7. Relapse-free Survival

    Relapse-free survival was measured only for participants who achieved a CR or CRh\* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse-free survival was estimated using Kaplan-Meier methods.

    Time frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.

  8. Overall Survival

    Overall survival was measured for all participants from the date of first infusion of blinatumomab until the date of death due to any cause. Participants who did not die were censored on the last documented visit date. Overall survival was estimated using Kaplan-Meier methods.

    Time frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 667 days.

  9. Number of Participants With Treatment-emergent Adverse Events

    Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 and according to the following: Grade I (mild); Grade 2 (moderate); Grade 3 (severe - significantly limits the patient's ability to perform routine activities despite symptomatic therapy; Grade 4 (life-threatening); Grade 5 (death). The investigator used medical judgment to determine if there was a causal relationship (ie, certain, probable, possible, unlikely, not related) between an adverse event and blinatumomab. A serious adverse event is any untoward medical occurrence or effect, that at any dose: resulted in death, was life-threatening, required or prolonged hospitalization, resulted in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is a medically important condition.

    Time frame: From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle; median treatment duration was 55.7 days.

  10. Steady State Blinatumomab Concentration

    The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the intravenous infusion was started for cycle 1 and cycle 2, respectively. Actual doses administered were used in the analysis. Concentrations below the limit of detection (3 pg/mL) were set to zero before data analysis and concentrations below the lower limit of quantitation (50 pg/mL) were excluded from analysis.

    Time frame: Samples were collected at predose and at 48 hours following start of infusion, when dose is escalated and on Days 8, 15, 22, and 29 of the first 2 cycles.

  11. Clearance of Blinatumomab

    Clearance was calculated as R0/Css; where R0 is the infusion rate (μg/m\^2/hr) and Css is the steady state concentration.

    Time frame: Samples were collected at predose and at 48 hours following start of infusion, when dose is escalated and on Days 8, 15, 22, and 29 of the first 2 cycles.

  12. Serum Cytokine Peak Levels

    The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) is 125 pg/mL and the limit of detection (LOD) is 20 pg/mL.

    Time frame: Samples were collected prior to treatment start (baseline), and at 2, 6, 24, and 48 hours after drug infusion start, and at these same time points when dose is escalated in each treatment cycle.

07

Results

Posted Jan 7, 2015

Participant flow

This study was open to adult patients with relapsed / refractory B-precursor acute lymphoblastic leukemia (ALL).

Participant flow — Overall Study
MilestoneBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μg
Started7236
Completed2133
Not completed5103
Withdrew: Adverse event431
Withdrew: Hematological relapse after remission011
Withdrew: Remission not achieved in 2 cycles131
Withdrew: Physician decision020
Withdrew: Other010

Outcome measures

PrimaryPercentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: Complete Response/Remission (CR): * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Full recovery of peripheral blood counts: * Platelets \> 100,000/μL * Hemoglobin ≥ 11 g/dL * Absolute neutrophil count (ANC) \> 1,500/μL Complete Remission with only Partial Hematological Recovery (CRh\*): * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Partial recovery of peripheral blood counts: * Platelets \> 50,000/μL * Hemoglobin ≥ 7 g/dL * ANC \> 500/μL.

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
percentage of participantsBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab Overall
Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment71.4 (29.0 to 96.3)69.6 (47.1 to 86.8)66.7 (22.3 to 95.7)69.4 (51.9 to 83.7)
SecondaryPercentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment

At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete Response/Remission (CR) was defined by the following criteria: * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Full recovery of peripheral blood counts: * Platelets \> 100,000/μL * Hemoglobin ≥ 11 g/dL * Absolute neutrophil count (ANC) \> 1,500/μL

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment
percentage of participantsBlinatumomab 15 μgBlinatumomab 5/15 μgABlinatumomab 5/15/30 μgBlinatumomab Overall
Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment14.3 (0.4 to 57.9)43.5 (23.2 to 65.5)66.7 (22.3 to 95.7)41.7 (25.5 to 59.2)
SecondaryPercentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete remission with only partial hematological recovery (CRh\*) was defined by the following criteria: * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Partial recovery of peripheral blood counts: * Platelets \> 50,000/μL * Hemoglobin ≥ 7 g/dL * ANC \> 500/μL.

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
percentage of participantsBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab Overall
Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment57.1 (18.4 to 90.1)26.1 (10.2 to 48.4)0.0 (0.0 to 45.9)27.8 (14.2 to 45.2)
SecondaryPercentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment

At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Partial remission was defined by the following criteria: • Bone marrow blasts ≤ 25%

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment
percentage of participantsBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab Overall
Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment0.0 (0.0 to 41.0)8.7 (1.1 to 28.0)0.0 (0.0 to 45.9)5.6 (0.7 to 18.7)
SecondaryPercentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study

A minimal residual disease (MRD) response is defined as MRD \< 10\^-4 blasts/nucleated cells based on polymerase chain reaction (PCR) evaluation of individual rearrangements of immunoglobulin or T cell receptor genes.

Time frame:
During the core study treatment period (up to 30 weeks).
Reported as:
Number · percentage of participants
Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study
percentage of participantsBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab Overall
Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study71.4 (29.0 to 96.3)73.9 (51.6 to 89.8)50.0 (11.8 to 88.2)69.4 (51.9 to 83.7)
SecondaryPercentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab

The percentage of participants who underwent immediate allogeneic HSCT (defined as those in remission who undergo HSCT without receiving any other treatments) after having discontinued or completed the core study.

Time frame:
Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab
percentage of participantsBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab42.960.916.750.0
SecondaryTime to Hematological Relapse

Time to hematological relapse was measured for participants who achieved a CR or CRh\* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their day of death. Hematological Relapse was defined as: * Proportion of blasts in bone marrow \> 5% * Extramedullary relapse. Time to hematological relapse was analyzed by Kaplan-Meier methods.

Time frame:
Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.
Reported as:
Median · days
Time to Hematological Relapse
daysBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumimab Overall
Time to Hematological Relapse240.0 (63.0 to 270.0)NA (227.0 to NA)NA (15.0 to NA)270.0 (227.0 to NA)
SecondaryRelapse-free Survival

Relapse-free survival was measured only for participants who achieved a CR or CRh\* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse-free survival was estimated using Kaplan-Meier methods.

Time frame:
Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.
Reported as:
Median · days
Relapse-free Survival
daysBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab Overall
Relapse-free Survival137.0 (63.0 to 270.0)268.0 (226.0 to 403.0)NA (15.0 to NA)233.0 (175.0 to 291.0)
SecondaryOverall Survival

Overall survival was measured for all participants from the date of first infusion of blinatumomab until the date of death due to any cause. Participants who did not die were censored on the last documented visit date. Overall survival was estimated using Kaplan-Meier methods.

Time frame:
Up to the data cut-off date of 15 October 2012; maximum follow up time was 667 days.
Reported as:
Median · days
Overall Survival
daysBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab Overall
Overall Survival269.0 (165.0 to 482.0)300.0 (254.0 to 431.0)NA (276.0 to NA)300.0 (258.0 to 455.0)
SecondaryNumber of Participants With Treatment-emergent Adverse Events

Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 and according to the following: Grade I (mild); Grade 2 (moderate); Grade 3 (severe - significantly limits the patient's ability to perform routine activities despite symptomatic therapy; Grade 4 (life-threatening); Grade 5 (death). The investigator used medical judgment to determine if there was a causal relationship (ie, certain, probable, possible, unlikely, not related) between an adverse event and blinatumomab. A serious adverse event is any untoward medical occurrence or effect, that at any dose: resulted in death, was life-threatening, required or prolonged hospitalization, resulted in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is a medically important condition.

Time frame:
From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle; median treatment duration was 55.7 days.
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events
participantsBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab Overall
Any adverse event (AE)723636
Adverse events of at least CTC grade 3715527
Treatment-related adverse events723636
Related adverse events of at least CTC grade 3712423
Serious adverse events613524
Serious adverse events of at least CTC grade 3612422
Serious related adverse events48416
AEs leading to interruption of blinatumomab36312
AEs leading to discontinuation of blinatumomab4419
AEs leading to death1416
SecondarySteady State Blinatumomab Concentration

The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the intravenous infusion was started for cycle 1 and cycle 2, respectively. Actual doses administered were used in the analysis. Concentrations below the limit of detection (3 pg/mL) were set to zero before data analysis and concentrations below the lower limit of quantitation (50 pg/mL) were excluded from analysis.

Time frame:
Samples were collected at predose and at 48 hours following start of infusion, when dose is escalated and on Days 8, 15, 22, and 29 of the first 2 cycles.
Reported as:
Mean · pg/mL
Steady State Blinatumomab Concentration
pg/mLBlinatumomab 5 μgBlinatumomab 15 μgBlinatumomab 30 μg
Steady State Blinatumomab Concentration167 ± 66553 ± 2381180 ± 820
SecondaryClearance of Blinatumomab

Clearance was calculated as R0/Css; where R0 is the infusion rate (μg/m\^2/hr) and Css is the steady state concentration.

Time frame:
Samples were collected at predose and at 48 hours following start of infusion, when dose is escalated and on Days 8, 15, 22, and 29 of the first 2 cycles.
Reported as:
Mean · L/m^2/hr
Clearance of Blinatumomab
L/m^2/hrBlinatumomab
Clearance of Blinatumomab1.34 ± 0.61
SecondarySerum Cytokine Peak Levels

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) is 125 pg/mL and the limit of detection (LOD) is 20 pg/mL.

Time frame:
Samples were collected prior to treatment start (baseline), and at 2, 6, 24, and 48 hours after drug infusion start, and at these same time points when dose is escalated in each treatment cycle.
Reported as:
Mean · pg/mL
Serum Cytokine Peak Levels
pg/mLBlinatumomab
IL-6: Cycle 1 (N=35)2563 ± 5231
IL-6: Cycle 2 (N=22)212 ± 477
IL-6: Cycle 3 (N=11)21 ± 26
IL-10: Cycle 1 (N=35)1302 ± 2563
IL-10: Cycle 2 (N=22)351 ± 582
IL-10: Cycle 3 (N=11)419 ± 730
IFN-Ɣ: Cycle 1 (N=35)467 ± 1824
IFN-Ɣ: Cycle 2 (N=22)25 ± 28
IFN-Ɣ: Cycle 3 (N=11)NA ± NA
IL-2: Cycle 1 (N=35)36 ± 49
IL-2: Cycle 2 (N=22)NA ± NA
IL-2: Cycle 3 (N=11)NA ± NA
TNF-α: Cycle 1 (N=35)60 ± 122
TNF-α: Cycle 2 (N=22)NA ± NA
TNF-α: Cycle 3 (N=11)NA ± NA

Adverse events

Collected over From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle; median treatment duration was 55.7 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinatumomab 15 μg—6/7 (85.7%)7/7 (100%)
Blinatumomab 5/15 μg—13/23 (56.5%)23/23 (100%)
Blinatumomab 5/15/30 μg—5/6 (83.3%)6/6 (100%)
Blinatumomab Overall—24/36 (66.7%)36/36 (100%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab Overall
Catheter site infectionInfections and infestations3/71/230/64/36
NauseaGastrointestinal disorders0/71/231/62/36
PyrexiaGeneral disorders1/71/231/63/36
Cytokine release syndromeImmune system disorders1/71/231/63/36
Candida sepsisInfections and infestations0/70/231/61/36
ConvulsionNervous system disorders0/71/231/62/36
EncephalopathyNervous system disorders1/71/231/63/36
TremorNervous system disorders0/72/231/63/36
Disseminated intravascular coagulationBlood and lymphatic system disorders1/70/230/61/36
LeukopeniaBlood and lymphatic system disorders1/70/230/61/36
Most frequent other events
Showing 10 of 165
Most frequent other events
EventBlinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgBlinatumomab Overall
PyrexiaGeneral disorders5/718/236/629/36
Oedema peripheralGeneral disorders6/75/233/614/36
FatigueGeneral disorders5/78/235/618/36
HeadacheNervous system disorders2/711/234/617/36
Gamma-glutamyltransferase increasedInvestigations4/73/230/67/36
Weight decreasedInvestigations4/72/232/68/36
HyperglycaemiaMetabolism and nutrition disorders4/70/230/64/36
DiarrhoeaGastrointestinal disorders3/76/233/612/36
ChillsGeneral disorders2/72/233/67/36
Weight increasedInvestigations3/77/233/613/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)Blinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgTotal
Mean44.0 ± 21.538.1 ± 16.742.5 ± 23.240.0 ± 18.4
Sex: Female, Male
Sex: Female, Male(Participants)Blinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgTotal
Female39214
Male414422
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Blinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White722635
More than one race0000
Unknown or Not Reported0000
Number of Prior Relapses
Number of Prior Relapses(participants)Blinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgTotal
00213
1515323
22619
30011
Relapsed / refractory Status
Relapsed / refractory Status(participants)Blinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgTotal
Primary Refractory0213
Relapsed721533
Prior Allogeneic Hematopoietic Stem cell Transplantation (HSCT)
Prior Allogeneic Hematopoietic Stem cell Transplantation (HSCT)(participants)Blinatumomab 15 μgBlinatumomab 5/15 μgBlinatumomab 5/15/30 μgTotal
Yes, Sibling1113
Yes, Unrelated29112
Yes, Haploidentical (mother/father)0000
No prior allogeneic HSCT413421
08

Study locations

9 sites
  • Frankfurt, Germany
  • Freiburg, Germany
  • Hannover, Germany
  • Kiel, Germany
  • Münster, Germany
  • Regensburg, Germany
  • Tübingen, Germany
  • Ulm, Germany
  • Würzburg, Germany
09

References and documents

Publications

  • Nagele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, Gokbuget N, Baeuerle PA, Kufer P, Wolf A, Klinger M. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Exp Hematol Oncol. 2017 May 18;6:14. doi: 10.1186/s40164-017-0074-5. eCollection 2017. PubMed 28533941 ↗
  • Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4. PubMed 27209293 ↗
  • Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Bruggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10. PubMed 25385737 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Mar 2012 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2010
First posted
Sep 27, 2010
Start
Oct 2010
Primary completionActual
Mar 2012
CompletionActual
Oct 2016
Results first posted
Jan 7, 2015
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01209286
Responsible party
Sponsor
First posted
Sep 27, 2010
Start date
Oct 2010
Primary completion
Mar 2012
Completion
Oct 2016
Results posted
Jan 7, 2015
Last update
Mar 6, 2017

Study contacts

Max Topp, MD
principal investigator · University of Wuerzburg

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion